Der Maus Monoklonal Anti-PD-L1-Antikörper wurde für WB, FACS, ELISA, IF, ICC und IHC (p) validiert. Er ist geeignet, PD-L1 in Proben von Human zu detektieren.
Produktnummer ABIN6992231
Kurzübersicht für PD-L1 Antikörper (Extracellular Domain) (ABIN6992231)
PD-L1
Reaktivität: Human
WB, IF, ICC
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
PD-L1 antibody can be used for detection of PD-L1 by Western blot at 0.25 - 0.5 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 2 - 5 μ,g/mL. For immunofluorescence start at 5 μ,g/mL.
Antibody validated: Western Blot in human samples, Immunohistochemistry in human samples, Immunocytochemistry in human samples, Immunofluorescence in human samples and Flow Cytometry in mouse samples. All other applications and species not yet tested.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
PD-L1 Antibody is supplied in PBS containing 0.02 % sodium azide and 50 % glycerol.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Lagerung
-20 °C,4 °C
Informationen zur Lagerung
PD-L1 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Target
PD-L1
(CD274 (PD-L1))
Andere Bezeichnung
PDL1
Hintergrund
PD-L1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antigen-presenting cells (APC) (1). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC (2). PD-1 can bind two different but related ligands, PD-L1 and PD-L2. PD-L1 is a B7-related protein that inhibits cell-mediated immune responses by reducing the secretion of IL-2 and IL-10 from memory T cells (3). This suggests that PD-L1 may be useful in reducing allogenic CD4+ memory T-cell responses to endothelial cells, thereby reducing the likelihood of host immune responses to allografts. PD-L1 also functions as an immune checkpoint protein, and multiple anti-PD-L1 antibodies are currently in phase II and III clinical trials, with one antibody already approved for the treatment of cancer (4).